| BACKGROUND
Asthma is a major public health problem affecting over 300 million people worldwide. 1 Its prevalence and impact are particularly on the rise and it is estimated that by 2025 an additional 100 million people may develop asthma. 2 Asthma is therefore set to become one of the world's most prevalent chronic diseases.
Based on the clinical history, examination and investigative procedures, different asthma phenotypes have been described. 3 The pathogenesis of asthma is extremely complex and several disease endotypes have been suggested. 3, 4 Allergic asthma is one of best described asthma phenotypes of primary studies. Allergic sensitization is a strong risk factor for asthma inception and severity in children and in adults. 
The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing Guidelines on Allergen
Immunotherapy (AIT) for Allergic Asthma. We undertook a systematic review of primary studies on the effectiveness, cost-effectiveness and safety of AIT for allergic asthma to inform the formulation of key clinical recommendations.
| ME TH ODS
A detailed outline of the methods have previously been published in the protocol of this review. 6 We therefore confine ourselves to a synopsis of the methods employed.
A highly sensitive search strategy was developed, and validated study design filters were applied to retrieve articles pertaining to the use of AIT for allergic asthma from electronic bibliographic databases. The search strategy was developed on OVID MEDLINE and then adapted for the other databases (see Appendix 1) . In all cases, the databases were searched from inception to 31 October 2015.
Additional papers were located through searching the references cited by the identified studies, and unpublished work and research in progress was identified through discussion with experts in the field.
There were no language restrictions employed.
Inclusion and exclusion criteria are detailed in Box 1.
| Study selection
All references were uploaded into the systematic review software DistillerSR and underwent de-duplication. Studies were independently checked by two reviewers (SD, FA or AK) against the above inclusion criteria. Any discrepancies were resolved through discussion and, when necessary, a third reviewer was consulted (AS).
| Quality assessment
Quality assessments were independently carried out on each study by two reviewers (FA, AK, DD, SD or MK). We used the Cochrane Risk of Bias (ROB) tool to assess RCTs, 9 the Critical Appraisal Skills Programme (CASP) Economic Evaluation Checklist for health economic studies, 10 and the National Institute for Health and Clinical Excellence (NICE) quality assessment tool to critically appraise case series. 11 Any discrepancies were resolved by discussion or arbitration by a third reviewer (AS).
| Data extraction, analysis and synthesis
Data were independently extracted onto a customized data extraction sheet in DistillerSR by two reviewers (FA, AK, HZ, DD or SD) and any discrepancies were resolved by discussion or arbitration by a third reviewer (AS). A descriptive report with summary data tables was produced to summarize the literature. Where clinically and statistically appropriate, meta-analyses were undertaken using random-effects modelling. 12 Where standardized mean difference (SMD) has been used the scale used is 0.2 represents a small effect size, 0.5 a medium effect size and 0.8 a large effect size. 105 
| Sensitivity and assessment for publication bias
Sensitivity analyses were, where possible, undertaken by comparing the summary estimates obtained by excluding studies judged to be at high ROB with those judged to be at low or moderate ROB.
BOX 1 Inclusion and exclusion criteria
Patient characteristics Studies conducted on patients of any age with a physician confirmed diagnosis of asthma, plus evidence of clinically relevant allergic sensitization as assessed by an objective biomarker (eg skin prick test or specific IgE), in combination with a history of asthma symptoms due to allergen exposure
Interventions of interest
AIT for different allergens (eg pollens, house dust mites (HDM), animal dander, cockroach and moulds), administered through either subcutaneous (SCIT) or sublingual (SLIT) routes.
Where possible, publication bias was assessed through the creation of funnel plots, and tested by Begg's rank correlation test and
Egger's regression test.
13,14
| Subgroup analyses
A number of subgroup analyses were undertaken, details of which are in the protocol.
| Registration and reporting
This review has been registered with the International Prospective
Register of Systematic Reviews (PROSPERO): CRD42016035372.
The Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) checklist was used to guide the reporting of the systematic review (Appendix 2).
| RESULTS
Our search strategy yielded 7490 papers of which 98 studies were eligible; these comprised 89 double-blind RCTs (reported in 94 papers), three cost-effectiveness studies and six case series (see Figure 1 ). Tables 1-3 and S1a-c.
| Quality assessment
The majority of SCIT trials (n=32) were judged as unclear ROB, seven low ROB and 15 studies as at high ROB (Table S1d) . Twenty SLIT studies were assessed to be at high ROB; 13 studies were at Studies included in quantitative synthesis (meta-analysis) N = 15 | 1835 unclear ROB; and one study at low ROB (Table S1e ). The one SCIT vs SLIT study was judged to be at a low ROB (Table S1f) . • SCIT vs SLIT: the analyses found that SCIT is effective with SMD À1.64 (95% CI À2.51, À0.78) and suggested (but did not confirm)
that SLIT was effective SMD À0.35 (95% CI À0.75, 0.05; Figure 4 ); this indirect comparison suggested that SCIT was more effective than SLIT.
• 
Long-term
No studies reported on the long-term effectiveness of AIT on symptom score.
| Medication scores
Short-term Sensitivity analysis Sensitivity analysis for this outcome was not possible as no studies were found to be at high ROB.
Publication bias The funnel plot showed possible publication bias as evidenced by an excess of small studies with large effect sizes (Fig. S2g ), but this was not confirmed by the Egger test (P=.09).
There were insufficient studies to undertake the Begg test.
Subgroup analyses
• Children (<18 years) vs adults (≥18 years): there is evidence for benefit in children SMD À0.49 (95% CI À0.98, 0.00) and a sug- • F I G U R E 6 Meta-analysis of doubleblind RCTs, comparing medication scores between AIT (SLIT and SCIT) and placebo groups in children <18 vs adults ≥18 y (random-effects model)
Long-term
No studies reported on the long-term effectiveness of AIT on medication score.
| Combined symptom and medication scores

Short-term
Six studies (two SCIT, three SLIT studies and one SCIT vs. SLIT)
reported a combined assessment of the effectiveness of AIT on symptoms and medication usage. Pooling of data was possible for two studies, this showing an SMD of 0.17 (95% CI À0.23, 0.58; Figure 8 ).
Sensitivity analysis, assessment of publication bias and subgroup analyses These analyses were not possible for this outcome.
Long-term
One SLIT study at low ROB reported on this outcome. A five-year Test of SMD = 0 : z = 0.84 P = .400 Heterogeneity chi-squared = 0.12 (d.f. = 1) P = .728 I-squared (variation in SMD attributable to heterogeneity) = 0.0% Estimate of between-study variance Tau-squared = 0.0000 F I G U R E 8 Meta-analysis of doubleblind RCTs, comparing combined symptom medication scores between AIT (SLIT and SCIT) and placebo groups (random-effects model)
tablets or placebo treatment period in grass pollen allergic patients followed by a two-year blinded observation period when no active treatment was administered. At the end of the five years the group who had received SLIT were found to have a significant improvement in combined asthma symptom and medication scores when compared to placebo for the whole five-year period (P=.049).
| Secondary outcomes 3.3.1 | Asthma control
Seven SLIT studies reported on a measure of asthma control (see Table S1g for details). 77, 78, 85, 88, 93, 98, 100 We were unable to pool data due to the differences in reporting of results. The one study at low ROB found that AIT did not improve asthma control. 98 We found no evidence to assess whether SCIT is effective in improving asthma control in allergic asthma patients.
| Quality of life
Eleven AIT trials reported on a measure of disease-specific QoL (Table S1h) .
Three SCIT studies, 19, 35, 40 all judged to be at low ROB, reported significant improvements in disease-specific QoL. Pooled data from two of these trials 19, 35 showed a large treatment effect with an SMD of À0.83 (95% CI À1.19, À0.47) in favour of SCIT ( Figure 9 ). Seven SLIT trials reported on disease-specific QoL. 77, 78, 83, 88, 93, 98, 100 We were unable to pool data from these studies for meta-analysis due to the variable reporting of results (Table 4 ).
The one low ROB trial of SLIT 98 showed no significant improvement in disease-specific QoL.
| Exacerbations
Six trials 69, 78, 80, 88, 91, 98 reported on asthma exacerbations, which were defined in a number of ways (Table S1i ). The one SCIT trial at low ROB 69 reported on exacerbations defined by the number of courses of oral corticosteroids required to restore asthma control found no significant difference between the SCIT and placebo groups (P-value not given). Five SLIT studies reported on exacerbations, which we were unable to pool due to variations in the ways in which trial results were reported.
In summary, focusing on the trials at low ROB, the Wang (2006) SCIT trial failed to demonstrate evidence of a reduction in exacerbations in those treated with AIT compared with those treated with placebo. Two SLIT trials reported a positive effect of AIT on asthma exacerbations, one in the context of reducing the dose of ICS.
| Lung function
Twenty-five studies, of variable quality, reported on measures of lung function: peak expiratory flow rate (PEFR), forced expiratory volume in 1 second (FEV1) and forced expiratory flow at 25%-75% of forced vital capacity (FEF 25%-75%). Data on these outcomes were recorded in a number of ways and at varying times throughout the study.
Peak expiratory flow rate (PEFR)
Fourteen studies reported on this outcome. 
Forced expiratory volume (FEV1)
Nine studies reported on FEV1. Reporting of data was varied. 18, 28, 43, 57, 73, 93, 96, 106, 107 (Table S1k) Forced expiratory flow at 25%-75% of forced vital capacity (FEF25-75)
We were able to pool data on FEF25-75 from three trials 72, 96, 107 and found an SMD of 0.83 (95% CI 0.31, 1.35), this suggesting a large beneficial effect of AIT (Fig. S4a) .
Test of SMD = 0 : z = 4.48 P = .000 Heterogeneity chi-squared = 0.02 (d.f. = 1) P = .893 I-squared (variation in SMD attributable to heterogeneity) = 0.0% Estimate of between-study variance Tau-squared = 0.0000 F I G U R E 9 Meta-analysis of doubleblind RCTs of AIT (SCIT and SLIT) vs placebo for asthma-specific quality of life (random-effects model)
In summary, the evidence identified from meta-analysis evaluating the effect of AIT on lung function in allergic asthma supports the effectiveness of AIT on small airways (FEF 25%-75%), but with no clear evidence of benefit on improving PEFR or FEV1.
| Bronchial provocation tests
Thirty-one trials reported on bronchial provocation tests. Twentyone trials looked at allergen-specific provocation tests and 18 studies evaluated nonspecific measures of bronchial hyperreactivity.
There was a wide variation in reporting of outcome data (Tables S1l,m) .
Allergen-specific airway hyperreactivity
Twenty-one trials performed allergen-specific bronchial provocation tests. 15, [17] [18] [19] [20] [21] [22] 25, 30, 31, 35, 44, 48, 53, 60, 62, 64, 67, 70, 82, 106 They were of variable quality and were mainly SCIT trials (n=20), SLIT being evaluated in only one trial. 82 (Table S1l) .
Pooled data from three SCIT studies demonstrated a large effect of AIT with an SMD of 0.93 (95% CI 0.08, 1.79; Fig. S4b ) Furthermore, there was evidence from eight high-quality RCTs that SCIT was effective in reducing allergen-specific bronchial reactivity in patients with allergic asthma.
One SLIT study reported on allergen-specific bronchial responsiveness to Artemisia pollen (Leng 1990 ). This study, at moderate ROB, found no significant difference between the SLIT and placebo groups.
Nonspecific airway hyperreactivity
Eighteen studies reported on this outcome. (Table S1m ). (Fig. S4d) .
| Cost-effectiveness
One SCIT and two SLIT studies satisfied the eligibility criteria. [108] [109] [110] These included children and adults with or without allergic rhinitis (Tables S1m,n). The quality appraisal is detailed in Tables S1o,p.
Of the three studies included only one focused on patients with allergic asthma who did not also have allergic rhinitis. 108 This study was carried out in Germany and compared SCIT with standard care based on a small scale RCT (N=65) with three years of follow-up data. The study used a disease-specific outcome measure (ie, mean morning peak flow) with no attempt to convert it to a general quality of life measure such as qualityadjusted life years (QALYs) making it impossible to assess the cost-effectiveness of the treatment. The study found that, over the three years, SCIT was more expensive than standard care and performed better than standard care on the disease-specific outcome measure.
The remaining two studies looked at patients with both asthma and allergic rhinitis. SLIT was compared with standard care in an RCT (N=151) with one year of follow-up conducted in Austria, Denmark, Germany, the Netherlands, Italy, Spain, Sweden and the UK, and with results evaluated from an English National Health Service (NHS) perspective. 109 This study used one year of treatment data and assumed a constant treatment effect over the three year treatment period and the six years following the end of the treatment. found that patients on SLIT cost less and experienced less symptoms than those on standard care. 110 Methods for calculating the costs were not presented in enough detail to understand the analysis that had been performed and there was no attempt to convert the symptom score to a general quality of life scale making it impossible to assess the cost-effectiveness of SLIT.
| Safety
Data from randomized controlled trials (RCTs) and case series were included to assess the safety of AIT.
| RCTs
Fifty-two RCTs (36 SCIT studies and 16 SLIT) reported safety data (Tables S3a-f ). We were able to pool data from 38 of these studies (SCIT=29; SLIT=9) including both local and systemic adverse events (AEs).
Risk of patients experiencing one or more AE
AIT delivered by any route (SCIT or SLIT) increased the risk of patients experiencing one or more AE (ie local and systemic) with a rate ratio ( (Fig. S3b,c) .
Total number of AEs reported
AIT delivered by any route (SCIT or SLIT) increased the risk of total AEs (ie local and/or systemic) with a RR=1.50 (95% CI 1.12, 2.02; 
Risk of systemic AEs
AIT delivered by any route (SCIT or SLIT) increased the risk of sys- Fig. S3h,i) .
Risk of local AEs
AIT delivered by any route was not found to increase the risk of local AEs: RR=1.18 (95% CI 0.83, 1.67; Fig. S3j ) The available data suggested that the risk of local AEs was however substantially greater in those receiving SLIT when compared to those receiving SCIT (Fig. S3j) .
Case series
We identified six eligible case series studies in our searches; SCIT These findings do however need to be interpreted with caution
given that the majority of trials were found to be at high or unclear ROB and the possibility of publication bias in relation to both these outcomes. Further subgroup analysis confirmed the beneficial effect for SCIT but was questionable for SLIT. There was a more modest body of evidence for the combined symptom and medication scores, which meta-analysis suggested was ineffective but this was not conclusively demonstrated on account of the wide confidence intervals. We found only one trial, judged to be at low ROB, evaluating long-term outcomes, which found a significant improvement in combined symptom and medication scores.
There is evidence for SCIT in improving asthma-specific quality of life and reducing allergen-specific airway hyperreactivity. In terms of lung function we were unable to demonstrate any significant ben- AIT was associated with a moderate increased risk of AEs, both for SCIT and SLIT. Severe systemic AEs were observed, but these were uncommon and mainly occurred with SCIT. No fatalities were reported in the studies included in this review.
| Strengths and limitations
To our knowledge, this is the most comprehensive assessment of AIT in asthma ever undertaken. We employed internationally accepted techniques to systematically identify, assess and synthesize a substantial body of evidence, which included a number of prespecified sensitivity and subgroup analyses.
The limitations of this review need to be considered. First, despite our extensive searches we may not have uncovered all relevant evidence on this subject. Second, we were limited by the heterogeneity in approaches used to assess outcomes, which meant we were unable to pool data from all trials or undertake all the planned subgroup analyses. The results of this review, particularly for primary outcomes, are based on the trials which we were able to meta-analyse which may not be representative of all trials. For example, data for combined scores were only available for six studies of which only two could be pooled for meta-analysis the results of which had a wide confidence interval allowing no clear conclusion to be drawn. For the subgroup analyses that were undertaken, there was in some cases imprecision which impacted on our ability to draw clear conclusions. Third, because of the heterogeneity in scoring systems used, we undertook metaanalyses using random-effects modelling and pooled data using SMDs, which can be difficult to interpret. The absolute size of the SMD was used to guide assessment of the likely effect size demonstrated. Finally, it needs to be borne in mind that there may have been important differences between specific AIT products. Investigating this issue was however beyond the scope of this review.
| Interpretation in the light of the previous literature
The findings from this review are in keeping with earlier evidence syntheses on this subject (see companion paper), which found that SCIT improved short-term symptom and medication scores and measures of bronchial reactivity, but the evidence for SLIT was less consistent. There was no clear improvement of lung function for either SCIT or SLIT. This present study has built on this body of work by adding a broader range of subgroup analyses, including additional studies at low ROB, and achieving greater precision in summary results.
| Implications for policy, practice and research
Our findings provide evidence that AIT may be effective in improving two of our three patient-reported primary outcomes over the short term. Interpretation of these results is however complicated by DHAMI ET AL.
| 1843
considerations about the quality of the substantial number of studies and possible publication bias. The subgroup analyses suggest that SCIT is likely to be more effective than SLIT, and that AIT may be more effective in children than in adults.
Greater standardization of trial designs, looking at the compliance of patients to AIT for the differing routes of administration, reporting and choice of outcomes and their reporting so as to facilitate evidence syntheses and key subgroup analyses would greatly help to advance the body of evidence underpinning AIT in allergic asthma.
Future well-conducted studies looking at the combined symptom and medication score are needed to determine whether AIT is beneficial for this outcome. We hope that future researchers will build on the findings from this systematic review and aim to fill key evidence gaps and areas of continuing uncertainty.
The findings from this review will be used to inform the development of recommendations for EAACI's Guidelines on AIT. We anticipate that this review will report mid 2017.
| CONCLUSIONS
There is evidence that AIT in allergic asthma can achieve substantial reductions in short-term symptom and medication scores, with subgroup analyses confirming a benefit from SCIT and a questionable benefit from SLIT. These findings however need to be interpreted with caution given concerns about study quality and potential publication bias. Further, there is evidence showing that SCIT decreases allergen-specific airway hyperreactivity and improves asthma-specific quality of life. The effect of AIT on asthma control and exacerbations is not conclusive, neither its long-term efficacy after stopping AIT, which requires further investigation. More research is needed to establish the cost-effectiveness of AIT, but evidence suggests that SLIT is cost-effective in a UK NHS environment.
AIT is associated with a modest increase in the risk of AEs, both for SCIT and SLIT. Severe systemic AEs can occur, but are uncommon and mainly associated with SCIT. No fatalities were reported in the studies included in this review.
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